2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide (BioDeep_00000172867)

   

human metabolite blood metabolite


代谢物信息卡片


2-Methyl-4-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide

化学式: C29H31N5O3 (497.2426776)
中文名称: GR 127935盐酸盐
谱图信息: 最多检出来源 Homo sapiens(blood) 94.12%

分子结构信息

SMILES: CC1=C(C=CC(=C1)C2=NOC(=N2)C)C3=CC=C(C=C3)C(=O)NC4=CC(=C(C=C4)OC)N5CCN(CC5)C
InChI: InChI=1S/C29H31N5O3/c1-19-17-23(28-30-20(2)37-32-28)9-11-25(19)21-5-7-22(8-6-21)29(35)31-24-10-12-27(36-4)26(18-24)34-15-13-33(3)14-16-34/h5-12,17-18H,13-16H2,1-4H3,(H,31,35)

描述信息

D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists

同义名列表

5 个代谢物同义名

2-Methyl-4-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide; N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)-[1,1-biphenyl]-4-carboxamide; 2-Methyl-4-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylate (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide; GR-127935; GR127935



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Fatemeh Gharishvandi, Alireza Abdollahi, Hamed Shafaroodi, Razieh Mohammad Jafari, Parvin Pasalar, Ahmad Reza Dehpour. Involvement of 5-HT1B/1D receptors in the inflammatory response and oxidative stress in intestinal ischemia/reperfusion in rats. European journal of pharmacology. 2020 Sep; 882(?):173265. doi: 10.1016/j.ejphar.2020.173265. [PMID: 32574671]
  • Kazumasa Matsumoto-Miyai, Erika Yamada, Eriko Shinzawa, Yoshihisa Koyama, Shoichi Shimada, Masaru Yoshizumi, Masahito Kawatani. Serotonergic regulation of distention-induced ATP release from the urothelium. American journal of physiology. Renal physiology. 2016 04; 310(7):F646-F655. doi: 10.1152/ajprenal.00024.2015. [PMID: 26582760]
  • Hua Sui, Hanchen Xu, Qing Ji, Xuan Liu, Lihong Zhou, Haiyan Song, Xiqiu Zhou, Yangxian Xu, Zhesheng Chen, Jianfeng Cai, Guang Ji, Qi Li. 5-hydroxytryptamine receptor (5-HT1DR) promotes colorectal cancer metastasis by regulating Axin1/β-catenin/MMP-7 signaling pathway. Oncotarget. 2015 Sep; 6(28):25975-87. doi: 10.18632/oncotarget.4543. [PMID: 26214021]
  • Nancy A Shanahan, Kerri A Holick Pierz, Virginia L Masten, Christian Waeber, Mark Ansorge, Jay A Gingrich, Mark A Geyer, Rene Hen, Stephanie C Dulawa. Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice. Biological psychiatry. 2009 Mar; 65(5):401-8. doi: 10.1016/j.biopsych.2008.09.026. [PMID: 19013555]
  • Nicole M E Carmichael, Milton P Charlton, Jonathan O Dostrovsky. Activation of the 5-HT1B/D receptor reduces hindlimb neurogenic inflammation caused by sensory nerve stimulation and capsaicin. Pain. 2008 Jan; 134(1-2):97-105. doi: 10.1016/j.pain.2007.03.037. [PMID: 17499925]
  • Minke E Jongsma, Fokko J Bosker, Thomas I F H Cremers, Ben H C Westerink, Johan A den Boer. The effect of chronic selective serotonin reuptake inhibitor treatment on serotonin 1B receptor sensitivity and HPA axis activity. Progress in neuro-psychopharmacology & biological psychiatry. 2005 Jun; 29(5):738-44. doi: 10.1016/j.pnpbp.2005.04.026. [PMID: 15961207]
  • David B Wainscott, Joseph H Krushinski, James E Audia, John M Schaus, John M Zgombick, Virginia L Lucaites, David L Nelson. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties. Naunyn-Schmiedeberg's archives of pharmacology. 2005 Mar; 371(3):169-77. doi: 10.1007/s00210-005-1035-9. [PMID: 15900510]
  • Elisabeth Marcos, Serge Adnot, Minh Hien Pham, Anne Nosjean, Bernadette Raffestin, Michel Hamon, Saadia Eddahibi. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. American journal of respiratory and critical care medicine. 2003 Aug; 168(4):487-93. doi: 10.1164/rccm.200210-1212oc. [PMID: 12773327]
  • A M Gardier, D J David, G Jego, C Przybylski, C Jacquot, S Durier, B Gruwez, E Douvier, P Beauverie, N Poisson, R Hen, M Bourin. Effects of chronic paroxetine treatment on dialysate serotonin in 5-HT1B receptor knockout mice. Journal of neurochemistry. 2003 Jul; 86(1):13-24. doi: 10.1046/j.1471-4159.2003.01827.x. [PMID: 12807420]
  • Eitan Gur, Eliyahu Dremencov, Francisca Garcia, Louis D Van de Kar, Bernard Lerer, Michael E Newman. Functional effects of chronic electroconvulsive shock on serotonergic 5-HT(1A) and 5-HT(1B) receptor activity in rat hippocampus and hypothalamus. Brain research. 2002 Oct; 952(1):52-60. doi: 10.1016/s0006-8993(02)03193-1. [PMID: 12363404]
  • V Fabre, C Beaufour, A Evrard, A Rioux, N Hanoun, K P Lesch, D L Murphy, L Lanfumey, M Hamon, M P Martres. Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors in knock-out mice lacking the 5-HT transporter. The European journal of neuroscience. 2000 Jul; 12(7):2299-310. doi: 10.1046/j.1460-9568.2000.00126.x. [PMID: 10947809]
  • T I Cremers, P de Boer, Y Liao, F J Bosker, J A den Boer, B H Westerink, H V Wikström. Augmentation with a 5-HT(1A), but not a 5-HT(1B) receptor antagonist critically depends on the dose of citalopram. European journal of pharmacology. 2000 May; 397(1):63-74. doi: 10.1016/s0014-2999(00)00247-8. [PMID: 10844100]
  • F M Cutrer, X J Yu, G Ayata, M A Moskowitz, C Waeber. Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis. Neuropharmacology. 1999 Jul; 38(7):1043-53. doi: 10.1016/s0028-3908(99)00032-5. [PMID: 10428423]
  • P De Vries, P A De Visser, J P Heiligers, C M Villalón, P R Saxena. Changes in systemic and regional haemodynamics during 5-HT7 receptor-mediated depressor responses in rats. Naunyn-Schmiedeberg's archives of pharmacology. 1999 Apr; 359(4):331-8. doi: 10.1007/pl00005359. [PMID: 10344532]
  • J M Zgombick, T A Branchek. Native 5-HT1B receptors expressed in OK cells display dual coupling to elevation of intracellular calcium concentrations and inhibition of adenylate cyclase. Naunyn-Schmiedeberg's archives of pharmacology. 1998 Nov; 358(5):503-8. doi: 10.1007/pl00005285. [PMID: 9840417]
  • X J Yu, F M Cutrer, M A Moskowitz, C Waeber. The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater. Neuropharmacology. 1997 Jan; 36(1):83-91. doi: 10.1016/s0028-3908(96)00149-9. [PMID: 9144644]
  • J E Leysen, W Gommeren, L Heylen, W H Luyten, I Van de Weyer, P Vanhoenacker, G Haegeman, A Schotte, P Van Gompel, R Wouters, A S Lesage. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Molecular pharmacology. 1996 Dec; 50(6):1567-80. doi: . [PMID: 8967979]
  • P Schoeffter, I Bobirnac. 5-Hydroxytryptamine 5-HT1D receptors mediating inhibition of cyclic AMP accumulation in Madin-Darby canine kidney (MDCK) cells. Naunyn-Schmiedeberg's archives of pharmacology. 1995 Sep; 352(3):256-62. doi: 10.1007/bf00168555. [PMID: 8584040]
  • P J Pauwels, C Palmier. Functional effects of the 5-HT1D receptor antagonist GR 127,935 at human 5-HT1D alpha, 5-HT1D beta, 5-HT1A and opossum 5-HT1B receptors. European journal of pharmacology. 1995 Jul; 290(2):95-103. doi: 10.1016/0922-4106(95)90021-7. [PMID: 8575538]